Total Payments
$1.2M
2024 Payments
$87,196
Companies
38
Transactions
658
Payment Breakdown by Category
Consulting$851,047 (72.7%)
Travel$134,384 (11.5%)
Other$103,046 (8.8%)
Research$60,795 (5.2%)
Food & Beverage$18,396 (1.6%)
Education$2,259 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $851,047 | 238 | 72.7% |
| Travel and Lodging | $134,384 | 148 | 11.5% |
| Unspecified | $60,795 | 11 | 5.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,386 | 17 | 5.1% |
| Honoraria | $43,660 | 13 | 3.7% |
| Food and Beverage | $18,396 | 228 | 1.6% |
| Education | $2,259 | 3 | 0.2% |
Payments by Type
General
$1.1M
647 transactions
Research
$60,795
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $172,731 | 116 | $0 (2024) |
| Grifols, S.A. | $157,862 | 14 | $0 (2022) |
| Biogen, Inc. | $153,091 | 75 | $0 (2024) |
| Merck Sharp & Dohme LLC | $74,047 | 81 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $68,891 | 36 | $0 (2023) |
| F. Hoffmann-La Roche AG | $68,552 | 28 | $0 (2024) |
| Novo Nordisk AS | $60,588 | 23 | $0 (2024) |
| Eli Lilly and Company | $60,338 | 28 | $0 (2024) |
| H. Lundbeck A S | $55,558 | 29 | $0 (2024) |
| Genentech USA, Inc. | $34,528 | 27 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,196 | 61 | Biogen, Inc. ($16,976) |
| 2023 | $110,293 | 76 | Novo Nordisk AS ($21,979) |
| 2022 | $167,602 | 102 | Biogen, Inc. ($44,888) |
| 2021 | $290,245 | 62 | Grifols, S.A. ($145,387) |
| 2020 | $71,315 | 37 | ACADIA Pharmaceuticals Inc ($25,820) |
| 2019 | $173,719 | 141 | Eisai Inc. ($45,312) |
| 2018 | $96,670 | 62 | F. Hoffmann-La Roche AG ($31,827) |
| 2017 | $172,888 | 117 | Eisai Inc. ($30,930) |
All Payment Transactions
658 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | H. Lundbeck A S | REXULTI (Drug) | Honoraria | Cash or cash equivalent | $8,775.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 11/25/2024 | Eli Lilly and Company | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: Neuroscience | ||||||
| 11/02/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $4,547.24 | General |
| 11/02/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| 11/02/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $112.58 | General |
| 11/02/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $70.35 | General |
| 11/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 11/01/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $228.88 | General |
| 11/01/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $70.59 | General |
| 10/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $2,070.06 | General |
| 10/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $198.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $198.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/02/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $3,510.00 | General |
| Category: Neurology | ||||||
| 10/02/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $313.57 | General |
| Category: Neurology | ||||||
| 09/26/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $4,485.00 | General |
| 09/26/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $2,193.00 | General |
| 09/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| 09/03/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,791.65 | General |
| 08/28/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $613.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN6535-4725 | Novo Nordisk AS | $13,770 | 3 |
| A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen, Inc. | $12,320 | 3 |
| A prospective longitudinal follow up study to access the ability of clinical outcome assessments to tract cognitive decline in Alzheimers disease (AD) | Novartis Pharmaceuticals Corporation | $10,000 | 1 |
| International Collaboration for Real-World Evidence in Alzheimers Disease (ICARE AD) - A Prospective Real-World Observational Study of Aducanumab-avwa in Patients with Alzheimers Disease in the US. | Biogen, Inc. | $7,345 | 1 |
| A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen, Inc. | $3,960 | 1 |
| HAEM 4436 | Novo Nordisk AS | $3,400 | 1 |
About Dr. Jeffrey Cummings, MD
Dr. Jeffrey Cummings, MD is a Neurology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457376329.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Cummings, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $87,196 received in 2024. These payments were reported across 658 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($851,047).
Ad
Practice Information
- Specialty Neurology
- Location Los Angeles, CA
- Active Since 07/13/2006
- Last Updated 09/02/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1457376329
Products in Payments
- ADUHELM (Biological) $64,740
- Non-Covered Product (Drug) $57,341
- NUPLAZID (Drug) $52,074
- REXULTI (Drug) $45,334
- Flebogamma DIF (Biological) $27,225
- Leqembi (Drug) $23,600
- None (Drug) $13,712
- DISEASE EDUCATION (Drug) $12,500
- RYBELSUS (Drug) $11,900
- Aricept (Drug) $9,895
- Albutein (Biological) $7,143
- MK-8931 (Drug) $6,069
- MK-8189 (Drug) $5,675
- BELSOMRA (Drug) $3,625
- Nuplazid (Drug) $2,877
- KISUNLA (Drug) $2,350
- ADLARITY (Drug) $2,240
- OCREVUS (Biological) $2,192
- IGALMI (Drug) $2,180
- NAMENDA (Drug) $1,988
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Los Angeles
Dr. Andrew Blumenfeld, M.d, M.D
Neurology — Payments: $6.2M
Neurology $6.2M
Dr. Alan Rapoport, M.d, M.D
Neurology — Payments: $1.0M
Neurology $1.0M
Said Beydoun, M.d, M.D
Neurology — Payments: $967,384
Neurology $967,384
Mark Lew, M.d, M.D
Neurology — Payments: $735,848
Neurology $735,848
Dr. Dawn Eliashiv, M.d, M.D
Neurology — Payments: $465,988
Neurology $465,988
Margaret Burnett, M.d, M.D
Neurology — Payments: $413,050
Neurology $413,050